高龄育龄妇女卵巢功能的激素优化与卵巢储备功能下降

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

论证。 在生殖医学领域,卵巢储备功能下降及其应对策略是当前研究的热点问题。除了积极探索卵巢功能激活的手术方法外,科学家们还在研究激素治疗的可能性。因此,全球学者的关注点集中在脱氢表雄酮(DHEA, dehydroepiandrosterone)的应用,以改善卵巢储备功能降低的高龄育龄期女性的生育状况。

目的。研究DHEA对高龄育龄妇女卵巢储备功能下降的影响,评估其对激素水平动态变化和卵巢储备指标的作用,并分析该组患者的妊娠及分娩率。

材料与方法。本研究纳入118名卵巢储备功能下降的高龄育龄妇女。所有患者均在月经周期第2-3天检测促卵泡生成激素(FSH, follicle-stimulating hormone)、黄体生成素(LH, luteinizing hormone)、雌二醇(E2,estradiol)、催乳素(PRL, prolactin)、抗缪勒管激素(AMH, anti-Müllerian hormone)和抑制素B(Inhibin B),并进行卵泡监测(超声评估窦卵泡数)。之后,给予患者 DHEA 75 mg/天,并在 3、6 和 8 个月后监测激素水平,同时重复进行超声卵泡监测。治疗结束后,分析患者数据并评估妊娠率。

结果。连续服用DHEA 75 mg/天 8个月后,患者FSH水平显著降低(9.91 [8.60; 10.90]),LH水平下降(7.63 [6.40; 8.60]),而E2水平升高(90.22 [78.90; 107.60];p <0.001)。 卵巢储备指标明显改善,体现在实验室参数的变化:AMH水平上升(1.08 [0.76; 1.40]), Inhibin B增加(98.38 [88.60; 111.40];p <0.001),以及超声指标的改善:窦卵泡数量增加至6-7枚。DHEA治疗显著减少月经周期紊乱的发生率,降至29.2%(118例患者中26例)。研究期间,31.3%(118例患者中37例)成功妊娠,其中62.1%(37例中23例)为自然妊娠,37.8%(37例中14例)通过体外受精(IVF, in vitro fertilization)受孕。最终,70.2%(37例中26例)成功分娩健康婴儿。自然流产率为29.7%(37例中11例)。

结论。对于卵巢储备功能下降的高龄育龄妇女,DHEA 75 mg/天的治疗方案在8个月内可显著改善卵巢储备功能指标,并提高妊娠成功率。

全文:

受限制的访问

作者简介

Lidiya A. Klyukina

I.M. Sechenov First Moscow State Medical University; Medical Center of Immunology and Reproduction

编辑信件的主要联系方式.
Email: lidiaklyukina@mail.ru
ORCID iD: 0000-0001-7602-4584
SPIN 代码: 1686-2663

Post-Graduate Student

俄罗斯联邦, 8 Trubetskaya st, bldg 2, Moscow, 119991; Moscow

Elena A. Sosnova

I.M. Sechenov First Moscow State Medical University

Email: sosnova-elena@inbox.ru
ORCID iD: 0000-0002-1732-6870
SPIN 代码: 6313-9959

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, 8 Trubetskaya st, bldg 2, Moscow, 119991

Igor I. Guzov

Medical Center of Immunology and Reproduction

Email: cir@cironline.ru
ORCID iD: 0000-0002-5628-8758

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

参考

  1. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev. 2009;30(5):465–493. doi: 10.1210/er.2009-0006
  2. Martirosyan YO, Silachev DN, Nazarenko TA, et al. Stem-cell-derived extracellular vesicles: unlocking new possibilities for treating diminished ovarian reserve and premature ovarian insufficiency. Life (Basel). 2023;13(12):2247. doi: 10.3390/life13122247
  3. Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787–808. doi: 10.1093/humupd/dmv036
  4. Tucker EJ, Grover SR, Bachelot A, et.al. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum. Endocr Rev. 2016;37(6):609–635. doi: 10.1210/er.2016-1047
  5. Bachelot A, Nicolas C, Bidet M, et al. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency. Clin Endocrinol (Oxf). 2017;86(2):223–228. doi: 10.1111/cen.13105
  6. Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18(1):73–91. doi: 10.1093/humupd/dmr039
  7. Smolnikova VYu, Kalinina EA, Krasnoshcheka OE, et al. Possibilities for noninvasive oocyte and embryo evaluation when implementing assisted reproductive technology programs for follicular-fluid growth factor MRNA expression. Akusherstvo i Ginekologiya. 2014;(9):36–43. EDN: STYIUP
  8. Labrie F, Luu-The V, Lin SX, et al. Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endoclinol Metab. 2000;11(10):421–427. doi: 10.1016/s1043-2760(00)00342-8
  9. Casson P. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Human Reproduction. 2000;15(10):2129–2132. doi: 10.1093/humrep/15.10.2129
  10. Nielsen M, Rasmussen I, Kristensen S, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Molecular Human Reproduction. 2010;17(1):63–70. doi: 10.1093/molehr/gaq073
  11. Ménézo Y, Dale B, Cohen M. DNA damage and repair in human oocytes and embryos: a review. Zygote. 2010;18(04):357–365. doi: 10.1017/s0967199410000286
  12. Mamas L, Mamas E. Premature ovarian failure and dehydroepiandrosterone. Fertility and Sterility. 2009;91(2):644–646. doi: 10.1016/j.fertnstert.2007.11.055
  13. Gleicher N, Weghofer A, Barad D. Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol. 2010;8:140. doi: 10.1186/1477-7827-8-140
  14. Zhang M, Niu W, Wang Y, et al. Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. J Assist Reprod Genet 2016;33(8):981–991. doi: 10.1007/s10815-016-0713-5
  15. Xu L, Hu C, Liu Q, Li Y. The effect of dehydroepiandrosterone (DHEA) supplementation on IVF or ICSI: a meta-analysis of randomized controlled trials. Geburtshilfe Frauenheilkd. 2019;79(7):705–712. doi: 10.1055/a-0882-3791

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2025



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ПИ № ФС 77 - 86335 от 11.12.2023 г.  
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:
ЭЛ № ФС 77 - 80633 от 15.03.2021 г.